The small molecule inhibitor QLT0267 Radiosensitizes squamous cell carcinoma cells of the head and neck.

BACKGROUND: The constant increase of cancer cell resistance to radio- and chemotherapy hampers improvement of patient survival and requires novel targeting approaches. Integrin-Linked Kinase (ILK) has been postulated as potent druggable cancer target. On the basis of our previous findings clearly sh...

Full description

Bibliographic Details
Main Authors: Iris Eke, Franziska Leonhardt, Katja Storch, Stephanie Hehlgans, Nils Cordes
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2009-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC2713401?pdf=render
id doaj-41b319e2a9294b728bde82315d2fe3b1
record_format Article
spelling doaj-41b319e2a9294b728bde82315d2fe3b12020-11-24T21:52:48ZengPublic Library of Science (PLoS)PLoS ONE1932-62032009-01-0147e643410.1371/journal.pone.0006434The small molecule inhibitor QLT0267 Radiosensitizes squamous cell carcinoma cells of the head and neck.Iris EkeFranziska LeonhardtKatja StorchStephanie HehlgansNils CordesBACKGROUND: The constant increase of cancer cell resistance to radio- and chemotherapy hampers improvement of patient survival and requires novel targeting approaches. Integrin-Linked Kinase (ILK) has been postulated as potent druggable cancer target. On the basis of our previous findings clearly showing that ILK transduces antisurvival signals in cells exposed to ionizing radiation, this study evaluated the impact of the small molecule inhibitor QLT0267, reported as putative ILK inhibitor, on the cellular radiation survival response of human head and neck squamous cell carcinoma cells (hHNSCC). METHODOLOGY/PRINCIPAL FINDINGS: Parental FaDu cells and FaDu cells stably transfected with a constitutively active ILK mutant (FaDu-IH) or empty vectors, UTSCC45 cells, ILK(floxed/floxed(fl/fl)) and ILK(-/-) mouse fibroblasts were used. Cells grew either two-dimensionally (2D) on or three-dimensionally (3D) in laminin-rich extracellular matrix. Cells were treated with QLT0267 alone or in combination with irradiation (X-rays, 0-6 Gy single dose). ILK knockdown was achieved by small interfering RNA transfection. ILK kinase activity, clonogenic survival, number of residual DNA double strand breaks (rDSB; gammaH2AX/53BP1 foci assay), cell cycle distribution, protein expression and phosphorylation (e.g. Akt, p44/42 mitogen-activated protein kinase (MAPK)) were measured. Data on ILK kinase activity and phosphorylation of Akt and p44/42 MAPK revealed a broad inhibitory spectrum of QLT0267 without specificity for ILK. QLT0267 significantly reduced basal cell survival and enhanced the radiosensitivity of FaDu and UTSCC45 cells in a time- and concentration-dependent manner. QLT0267 exerted differential, cell culture model-dependent effects with regard to radiogenic rDSB and accumulation of cells in the G2 cell cycle phase. Relative to corresponding controls, FaDu-IH and ILK(fl/fl) fibroblasts showed enhanced radiosensitivity, which failed to be antagonized by QLT0267. A knockdown of ILK revealed no change in clonogenic survival of the tested cell lines as compared to controls. CONCLUSIONS/SIGNIFICANCE: Our data clearly show that the small molecule inhibitor QLT0267 has potent cytotoxic and radiosensitizing capability in hHNSCC cells. However, QLT0267 is not specific for ILK. Further in vitro and in vivo studies are necessary to clarify the potential of QLT0267 as a targeted therapeutic in the clinic.http://europepmc.org/articles/PMC2713401?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Iris Eke
Franziska Leonhardt
Katja Storch
Stephanie Hehlgans
Nils Cordes
spellingShingle Iris Eke
Franziska Leonhardt
Katja Storch
Stephanie Hehlgans
Nils Cordes
The small molecule inhibitor QLT0267 Radiosensitizes squamous cell carcinoma cells of the head and neck.
PLoS ONE
author_facet Iris Eke
Franziska Leonhardt
Katja Storch
Stephanie Hehlgans
Nils Cordes
author_sort Iris Eke
title The small molecule inhibitor QLT0267 Radiosensitizes squamous cell carcinoma cells of the head and neck.
title_short The small molecule inhibitor QLT0267 Radiosensitizes squamous cell carcinoma cells of the head and neck.
title_full The small molecule inhibitor QLT0267 Radiosensitizes squamous cell carcinoma cells of the head and neck.
title_fullStr The small molecule inhibitor QLT0267 Radiosensitizes squamous cell carcinoma cells of the head and neck.
title_full_unstemmed The small molecule inhibitor QLT0267 Radiosensitizes squamous cell carcinoma cells of the head and neck.
title_sort small molecule inhibitor qlt0267 radiosensitizes squamous cell carcinoma cells of the head and neck.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2009-01-01
description BACKGROUND: The constant increase of cancer cell resistance to radio- and chemotherapy hampers improvement of patient survival and requires novel targeting approaches. Integrin-Linked Kinase (ILK) has been postulated as potent druggable cancer target. On the basis of our previous findings clearly showing that ILK transduces antisurvival signals in cells exposed to ionizing radiation, this study evaluated the impact of the small molecule inhibitor QLT0267, reported as putative ILK inhibitor, on the cellular radiation survival response of human head and neck squamous cell carcinoma cells (hHNSCC). METHODOLOGY/PRINCIPAL FINDINGS: Parental FaDu cells and FaDu cells stably transfected with a constitutively active ILK mutant (FaDu-IH) or empty vectors, UTSCC45 cells, ILK(floxed/floxed(fl/fl)) and ILK(-/-) mouse fibroblasts were used. Cells grew either two-dimensionally (2D) on or three-dimensionally (3D) in laminin-rich extracellular matrix. Cells were treated with QLT0267 alone or in combination with irradiation (X-rays, 0-6 Gy single dose). ILK knockdown was achieved by small interfering RNA transfection. ILK kinase activity, clonogenic survival, number of residual DNA double strand breaks (rDSB; gammaH2AX/53BP1 foci assay), cell cycle distribution, protein expression and phosphorylation (e.g. Akt, p44/42 mitogen-activated protein kinase (MAPK)) were measured. Data on ILK kinase activity and phosphorylation of Akt and p44/42 MAPK revealed a broad inhibitory spectrum of QLT0267 without specificity for ILK. QLT0267 significantly reduced basal cell survival and enhanced the radiosensitivity of FaDu and UTSCC45 cells in a time- and concentration-dependent manner. QLT0267 exerted differential, cell culture model-dependent effects with regard to radiogenic rDSB and accumulation of cells in the G2 cell cycle phase. Relative to corresponding controls, FaDu-IH and ILK(fl/fl) fibroblasts showed enhanced radiosensitivity, which failed to be antagonized by QLT0267. A knockdown of ILK revealed no change in clonogenic survival of the tested cell lines as compared to controls. CONCLUSIONS/SIGNIFICANCE: Our data clearly show that the small molecule inhibitor QLT0267 has potent cytotoxic and radiosensitizing capability in hHNSCC cells. However, QLT0267 is not specific for ILK. Further in vitro and in vivo studies are necessary to clarify the potential of QLT0267 as a targeted therapeutic in the clinic.
url http://europepmc.org/articles/PMC2713401?pdf=render
work_keys_str_mv AT iriseke thesmallmoleculeinhibitorqlt0267radiosensitizessquamouscellcarcinomacellsoftheheadandneck
AT franziskaleonhardt thesmallmoleculeinhibitorqlt0267radiosensitizessquamouscellcarcinomacellsoftheheadandneck
AT katjastorch thesmallmoleculeinhibitorqlt0267radiosensitizessquamouscellcarcinomacellsoftheheadandneck
AT stephaniehehlgans thesmallmoleculeinhibitorqlt0267radiosensitizessquamouscellcarcinomacellsoftheheadandneck
AT nilscordes thesmallmoleculeinhibitorqlt0267radiosensitizessquamouscellcarcinomacellsoftheheadandneck
AT iriseke smallmoleculeinhibitorqlt0267radiosensitizessquamouscellcarcinomacellsoftheheadandneck
AT franziskaleonhardt smallmoleculeinhibitorqlt0267radiosensitizessquamouscellcarcinomacellsoftheheadandneck
AT katjastorch smallmoleculeinhibitorqlt0267radiosensitizessquamouscellcarcinomacellsoftheheadandneck
AT stephaniehehlgans smallmoleculeinhibitorqlt0267radiosensitizessquamouscellcarcinomacellsoftheheadandneck
AT nilscordes smallmoleculeinhibitorqlt0267radiosensitizessquamouscellcarcinomacellsoftheheadandneck
_version_ 1725874883594813440